Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-Azaxanthine is a synthetic purine analog in which the carbon at position 8 of the xanthine ring is replaced by a nitrogen atom. It belongs to the triazolopyrimidine family and has notable photophysical properties such as strong fluorescence due to excited-state proton transfer (ESPT), making it useful as a molecular probe in biochemical research[5][7]. Biologically, it acts primarily as an inhibitor of urate oxidase (urate oxidase catalyzes oxidation of uric acid to allantoin) and also inhibits adenosine receptors[5]. These activities have made it valuable for studying enzyme-ligand interactions and receptor-binding mechanisms. Additionally, it demonstrates antibacterial activity against Pseudomonas aeruginosa and Trypanosoma cruzi[5]. Its main use is experimental; there are no approved medical indications or clinical trials for therapeutic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-azaxanthine.